Emyria

D4, 661 Newcastle Street
Leederville WA 6007

Home

Contact Us

Updates

Corporate Governance

Annual Reports

Share Price

Announcements

New investors

Why Invest in Emyria?

Investor Research

Loyalty Option Offer

Presentations

Successes

Meet the Team

About Emyria

Webinars

Montserrat

Emyria Limited

Australian Financial Review | January 2024

upload.jpg

Emyria has been featured on page 12 of the Australian Financial Review, in an article by journalist Tom Rabe titled “The company using MDMA to treat post-traumatic stress”.

Speaking with CEO and MD, Dr Michael Winlo, and Emyria’s lead psychiatrist, Dr Jon Laugharne, the author highlights Emyria’s leading work evaluating the potential of MDMA as a community-based treatment approach for PTSD, which is estimated to affect close to 1 million Australians.

“The qualities that make MDMA an attractive party drug also prove a helpful adjunct to psychotherapy, according to Emyria managing director and chief executive Michael Winlo, who said it decreased a patient’s fear, while increasing compassion and trust.

“Under those influences one can approach more challenging content with an open mind, that’s why it’s potentially so powerful for therapy,” Dr Winlo said.

Earlier this month, Emyria announced that it had received authorised prescriber status from the Therapeutic Goods Administration.